A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Trial Profile

A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Tamibarotene (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Sponsors Syros Pharmaceuticals
  • Most Recent Events

    • 21 Jul 2017 According to a Syros Pharmaceuticals media release, the company plans to present initial data from the study in the fall 2017.
    • 21 Jul 2017 According to a Syros Pharmaceuticals media release, foundational data from the study were published online in Cancer Discovery, a peer-reviewed journal of the American Association of Cancer Research.
    • 21 Jul 2017 Foundational data from the study published in a Syros Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top